The	O 0 3
appearance	O 4 14
of	O 15 17
new	O 18 21
or	O 22 24
recurrent	O 25 34
objective	O 35 44
signs	O 45 50
of	O 51 53
Lyme	B-KP 54 58
disease	I-KP 59 66
after	O 67 72
antibiotic	B-KP 73 83
therapy	I-KP 84 91
should	O 92 98
prompt	O 99 105
evaluation	O 106 116
for	O 117 120
reinfection	O 121 132
or	O 133 135
incomplete	O 136 146
treatment	O 147 156
.	 O 156 157

A	O 158 159
recent	O 160 166
study	O 167 172
in	O 173 175
which	O 176 181
the	O 182 185
causative	O 186 195
strain	O 196 202
of	O 203 205
B	B-KP 206 207
burgdorferi	I-KP 208 219
was	O 220 223
cultured	O 224 232
from	O 233 237
EM	B-KP 238 240
lesions	I-KP 241 248
showed	O 249 255
that	O 256 260
recurrent	O 261 270
EM	B-KP 271 273
after	O 274 279
treatment	O 280 289
was	O 290 293
due	O 294 297
to	O 298 300
reinfection	O 301 312
rather	O 313 319
than	O 320 324
a	O 325 326
relapse	O 327 334
of	O 335 337
the	O 338 341
previously	O 342 352
treated	O 353 360
infection	O 361 370
[	 O 371 372
46	O 372 374
]	 O 374 375
.	 O 375 376

In	O 377 379
25	O 380 382
%	 O 382 383
of	O 384 386
patients	O 387 395
with	O 396 400
EM	B-KP 401 403
,	 O 403 404
clinical	O 405 413
disease	O 414 421
resolves	O 422 430
but	O 431 434
fatigue	O 435 442
,	 O 442 443
cognitive	O 444 453
problems	O 454 462
,	 O 462 463
or	O 464 466
joint	O 467 472
and	O 473 476
muscle	O 477 483
aches	O 484 489
persist	O 490 497
at	O 498 500
3	O 501 502
months	O 503 509
after	O 510 515
treatment	O 516 525
;	 O 525 526
this	O 527 531
percentage	O 532 542
decreases	O 543 552
to	O 553 555
10	O 556 558
%	 O 558 559
at	O 560 562
6	O 563 564
months	O 565 571
.	 O 571 572

Posttreatment	B-KP 573 586
Lyme	I-KP 587 591
disease	I-KP 592 599
syndrome	I-KP 600 608
(	 O 609 610
PTLDS	B-KP 610 615
)	 O 615 616
refers	O 617 623
to	O 624 626
such	O 627 631
symptoms	O 632 640
that	O 641 645
last	O 646 650
for	O 651 654
6	O 655 656
months	O 657 663
after	O 664 669
a	O 670 671
documented	O 672 682
episode	O 683 690
of	O 691 693
Lyme	O 694 698
disease	O 699 706
and	O 707 710
are	O 711 714
disabling	O 715 724
.	 O 724 725

The	O 726 729
frequency	O 730 739
with	O 740 744
which	O 745 750
PTLDS	B-KP 751 756
occurs	O 757 763
is	O 764 766
believed	O 767 775
to	O 776 778
be	O 779 781
substantially	O 782 795
below	O 796 801
10	O 802 804
%	 O 804 805
.	 O 805 806

PTLDS	B-KP 807 812
should	O 813 819
not	O 820 823
be	O 824 826
confused	O 827 835
with	O 836 840
"	 O 841 842
chronic	B-KP 842 849
Lyme	I-KP 850 854
disease	I-KP 855 862
.	 O 862 863
"	 O 863 864
This	O 865 869
name	O 870 874
originally	O 875 885
referred	O 886 894
to	O 895 897
late	O 898 902
manifestations	O 903 917
of	O 918 920
the	O 921 924
disease	O 925 932
,	 O 932 933
but	O 934 937
has	O 938 941
been	O 942 946
usurped	O 947 954
as	O 955 957
a	O 958 959
label	O 960 965
for	O 966 969
clinical	O 970 978
syndromes	O 979 988
that	O 989 993
may	O 994 997
or	O 998 1000
may	O 1001 1004
not	O 1005 1008
be	O 1009 1011
associated	O 1012 1022
with	O 1023 1027
previous	O 1028 1036
Lyme	O 1037 1041
borrelia	O 1042 1050
exposure	O 1051 1059
[	 O 1060 1061
47	O 1061 1063
]	 O 1063 1064
.	 O 1064 1065

The	O 1066 1069
reasons	O 1070 1077
for	O 1078 1081
persistence	O 1082 1093
of	O 1094 1096
symptoms	O 1097 1105
in	O 1106 1108
some	O 1109 1113
patients	O 1114 1122
after	O 1123 1128
treatment	O 1129 1138
for	O 1139 1142
Lyme	O 1143 1147
disease	O 1148 1155
are	O 1156 1159
not	O 1160 1163
known	O 1164 1169
.	 O 1169 1170

Theories	O 1171 1179
include	O 1180 1187
residual	O 1188 1196
damage	O 1197 1203
to	O 1204 1206
tissue	O 1207 1213
,	 O 1213 1214
slow	O 1215 1219
resolution	O 1220 1230
of	O 1231 1233
the	O 1234 1237
inflammatory	O 1238 1250
state	O 1251 1256
,	 O 1256 1257
and	O 1258 1261
/	O 1261 1262
or	O 1262 1264
a	O 1265 1266
form	O 1267 1271
of	O 1272 1274
cytokine-induced	O 1275 1291
sickness	O 1292 1300
behavior	O 1301 1309
due	O 1310 1313
to	O 1314 1316
previously	O 1317 1327
high	O 1328 1332
levels	O 1333 1339
of	O 1340 1342
circulating	O 1343 1354
cytokines	O 1355 1364
.	 O 1364 1365

Systemic	B-KP 1366 1374
inflammatory	I-KP 1375 1387
cytokines	I-KP 1388 1397
exert	O 1398 1403
adverse	O 1404 1411
effects	O 1412 1419
on	O 1420 1422
neurobehavioral	O 1423 1438
function	O 1439 1447
in	O 1448 1450
other	O 1451 1456
conditions	O 1457 1467
,	 O 1467 1468
independent	O 1469 1480
of	O 1481 1483
a	O 1484 1485
central	B-KP 1486 1493
nervous	I-KP 1494 1501
system	I-KP 1502 1508
infection	I-KP 1509 1518
[	 O 1519 1520
8	O 1520 1521
]	 O 1521 1522
.	 O 1522 1523

Nonspecific	O 1524 1535
symptoms	O 1536 1544
such	O 1545 1549
as	O 1550 1552
fatigue	O 1553 1560
and	O 1561 1564
pain	O 1565 1569
are	O 1570 1573
common	O 1574 1580
in	O 1581 1583
the	O 1584 1587
general	O 1588 1595
population	O 1596 1606
as	O 1607 1609
well	O 1610 1614
.	 O 1614 1615

